Amyloidosis, Hereditary Clinical Trial
Official title:
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05974644 -
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
|
||
| Recruiting |
NCT05879874 -
Prospective Evaluation of NfL as a Biomarker in ATTRv
|
||
| Recruiting |
NCT05489549 -
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
|
||
| Active, not recruiting |
NCT03759379 -
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
|
Phase 3 | |
| Completed |
NCT02319005 -
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
|
Phase 3 | |
| Recruiting |
NCT05873868 -
Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
|
||
| No longer available |
NCT02939820 -
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
|
||
| Approved for marketing |
NCT03400098 -
ATTR Expanded Access Program (EAP) by Ionis
|